Harrow vs Vanda Pharmaceuticals
Harrow is the larger business, with $272m of revenue in fiscal 2025 against $216m for Vanda Pharmaceuticals (1.3 times as much). Harrow grew faster (36.4% against 8.7%). Harrow kept more of each dollar of sales as profit: a net margin of -1.9% against -102.0%.
| Latest fiscal year | HarrowHROW, 2025 | Vanda PharmaceuticalsVNDA, 2025 |
|---|---|---|
| Revenue | $272m | $216m |
| Revenue growth | 36.4% | 8.7% |
| Net income | −$5.1m | −$220m |
| Operating margin | — | -70.0% |
| Net margin | -1.9% | -102.0% |
| Return on equity | -8.4% | -50.9% |
| Free cash flow | $43.0m | −$110m |
| Cash | $72.9m | $84.9m |
| Total debt | $250m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 533 |
| Market value | $1.06bn | $225m |
| Price vs our value range | Above our value range | — |
| Moat score | 26 (Weak) | 49 (Moderate) |
| Insider trades, 12 months | 4 buys, 7 sales | 0 buys, 6 sales |